Red Light Therapy During Pregnancy: Safety Review

Red light therapy has established safety profiles for skin rejuvenation, pain management, and wound healing in the general population. But pregnancy changes the calculus. The question isn’t simply “is red light therapy safe?” — it’s “is there sufficient evidence to confirm safety during pregnancy, where the stakes include a developing foetus?”

The honest answer: there isn’t enough evidence to make a definitive safety claim. But there’s also no evidence of harm. This article examines what we actually know, what we don’t, and what a reasonable, conservative approach looks like.

The Current Evidence Landscape

What Exists

The photobiomodulation (PBM) literature contains thousands of studies across dozens of clinical applications. However, pregnancy-specific research is remarkably sparse. A PubMed search for “photobiomodulation pregnancy” or “low-level laser therapy pregnancy” returns a small number of results, and nearly all fall into one of three categories:

1. Animal studies examining light exposure effects on embryonic development
2. Fertility studies using PBM as an adjunct to IVF or for egg quality improvement
3. Dental LLLT studies that happened to include pregnant patients (usually excluded or noted as a subgroup)

There are no large-scale randomised controlled trials specifically designed to assess the safety of red light therapy during human pregnancy. This gap isn’t because evidence of harm exists — it’s because pregnancy studies are ethically complex to design and fund, and PBM researchers have focused on other applications.

What Doesn’t Exist

• No published case reports of adverse pregnancy outcomes attributed to red or near-infrared light therapy
• No animal studies showing teratogenic effects of red/NIR light at therapeutic doses
• No mechanistic rationale for how low-level red/NIR light could harm a foetus

The absence of evidence is not evidence of absence — a principle that must be taken seriously when discussing pregnancy safety. But it’s worth noting that red and near-infrared light therapy has been used clinically since the 1960s, and the lack of any reported adverse pregnancy outcomes in over 60 years of use is itself a data point.

Why Red Light Therapy Is Unlikely to Be Harmful

Understanding the physics and biology helps contextualise the risk.

Penetration Depth

Red light (630-670nm) penetrates approximately 8-10mm into tissue. Near-infrared (810-850nm) penetrates deeper — up to 40-50mm in some tissue types (Henderson & Morries, 2015). These penetration depths are clinically significant for skin, subcutaneous tissue, and superficial musculoskeletal structures.

However, during pregnancy, the uterus and developing foetus are located deep within the abdominal cavity, behind layers of skin, subcutaneous fat, abdominal muscle, peritoneum, and the uterine wall itself. The total tissue barrier between external light and the foetus is typically 50-100mm or more, depending on body composition and gestational age.

At therapeutic irradiance levels (20-100 mW/cm² at the skin surface), the light reaching foetal depth would be attenuated by many orders of magnitude — effectively zero. Even if light could reach the foetus at detectable levels, the irradiance would be so far below any conceivable biological threshold as to be physically insignificant.

Non-Ionising Radiation

Red and near-infrared light are non-ionising radiation. Unlike ultraviolet light, X-rays, or gamma rays, these wavelengths do not have sufficient photon energy to damage DNA, cause mutations, or disrupt molecular bonds. The photon energy of 660nm red light is approximately 1.88 eV — far below the ~4 eV threshold needed for direct DNA damage (Hamblin & Demidova, 2006).

This is a fundamental distinction from the ionising radiation that poses genuine pregnancy risks. Red light therapy operates on the same portion of the electromagnetic spectrum as the light that passes through your skin every time you go outdoors.

Thermal Effects

At standard treatment parameters, red light therapy produces minimal tissue heating — typically less than 1 degree Celsius at the treatment surface (Huang et al., 2009). Core body temperature elevation is a known teratogenic risk factor, but the thermal effect of surface PBM is localised and too small to affect core temperature.

For context, a hot bath raises core temperature more significantly than a red light therapy panel does.

The Fertility Evidence

While pregnancy safety data is limited, there’s a growing body of research on PBM for fertility enhancement — which provides relevant adjacent evidence.

Egg Quality and Ovarian Function

Poormoosavi et al. (2017) demonstrated in an animal model that 830nm low-level laser therapy improved ovarian function and follicular development. The study suggested that PBM enhanced mitochondrial function in oocytes (egg cells), which is consistent with the general mechanism of photobiomodulation — cytochrome c oxidase activation leading to increased ATP production.

Ohkura et al. (2012) published preliminary data on LLLT applied to the reproductive area in women undergoing IVF, reporting improved pregnancy rates in the treatment group. The study was small and non-randomised, but it demonstrated that clinicians were willing to use PBM in a fertility context, implying a level of confidence in its safety profile.

IVF Adjunct Research

Several fertility clinics, particularly in Japan, have explored PBM as an adjunct to IVF treatment. The theoretical basis is compelling: age-related fertility decline is strongly associated with mitochondrial dysfunction in oocytes (Van Blerkom, 2011). If PBM can enhance mitochondrial function — as it demonstrably does in other cell types — it may improve egg quality in women with diminished ovarian reserve.

Sato et al. (2012) reported that proximal LLLT (applied to the neck/trunk area, not directly to the abdomen) was associated with improved pregnancy rates in IVF patients who had previously experienced repeated failures. The mechanism proposed was systemic improvement in blood flow and cellular metabolism rather than direct ovarian irradiation.

The fertility evidence is relevant to the pregnancy safety question because these studies involved women who were actively trying to become pregnant — and in some cases, women who became pregnant during or shortly after treatment. No adverse outcomes were reported in any of these studies.

Important Caveat

The fertility studies generally applied PBM before conception or during the pre-implantation period, not during established pregnancy. They don’t directly address safety during the critical periods of organogenesis (weeks 3-8) or later foetal development.

Breastfeeding Safety

The safety profile of red light therapy during breastfeeding is considerably less concerning than during pregnancy, for straightforward physiological reasons.

Red and near-infrared light do not introduce any substance into the body — there is no drug, chemical, or foreign material that could pass into breast milk. PBM works by modulating existing cellular processes (mitochondrial function, inflammatory signalling) through photon absorption. These effects are localised to the treated tissue.

Treating areas away from the breasts (e.g., face, back, legs) during breastfeeding has no plausible mechanism for affecting milk composition or infant health. Even treating the breast area directly — for example, for mastitis or nipple healing (for which there is some preliminary evidence) — would affect only the superficial tissue at the treatment site.

Recommendation: There are no evidence-based reasons to avoid red light therapy during breastfeeding. Standard treatment protocols for skin, pain, and recovery are appropriate. If treating the breast area directly, ensure the device is clean and avoid applying directly over the nipple immediately before feeding (not because of light exposure, but for basic hygiene).

What Practitioners Recommend

In the absence of definitive clinical trial data, healthcare practitioners who work with PBM have converged on a set of conservative recommendations.

Common Practitioner Guidance

1. Avoid direct abdominal exposure during pregnancy. This is the most consistent recommendation across practitioners, device manufacturers, and PBM textbooks. While the theoretical risk is extremely low (light can’t reach the foetus at therapeutic irradiance), the precautionary principle applies when evidence is insufficient.

2. Treatment of non-abdominal areas is generally considered acceptable. Treating the face, hands, feet, upper back, or extremities does not expose the uterine area to light. These treatments are considered low-risk by most practitioners.

3. First trimester caution. Some practitioners recommend avoiding all PBM during the first trimester (weeks 1-12), when organogenesis occurs and the developing embryo is most vulnerable to any environmental influence. This is an ultra-conservative position — there’s no specific evidence suggesting first-trimester risk from PBM — but it reflects the general medical approach to pregnancy safety.

4. Consult your midwife or obstetrician. Any treatment during pregnancy should be discussed with your prenatal care provider. They may not be familiar with PBM specifically, but they can assess your individual risk factors and make informed recommendations.

What Device Manufacturers Say

Most red light therapy device manufacturers include pregnancy as a contraindication or precaution in their user manuals. This is a liability-driven position rather than an evidence-based one — manufacturers cannot claim safety in the absence of pregnancy-specific clinical trials, so they default to recommending against use.

This doesn’t mean the devices are unsafe during pregnancy. It means manufacturers haven’t invested in the clinical trials needed to make an affirmative safety claim, and their legal teams prefer the cautious approach.

Areas to Avoid During Pregnancy

Based on the precautionary principle and practitioner consensus, the following areas should be avoided during pregnancy:

Direct Abdominal Exposure

Do not aim a red light therapy panel, wrap, or handheld device directly at the abdomen during pregnancy. While the physics strongly suggest that no therapeutically relevant light would reach the foetus, this remains the primary area of concern.

This includes:

• Full-body panel treatments aimed at the front of the torso
• Abdominal wraps or belts
• Handheld devices used on the stomach

Lower Back (Direct Targeting)

The lower back overlies the uterus, particularly in the second and third trimesters as the uterus expands. Direct, prolonged NIR exposure to the lower back could theoretically deliver some photons to the posterior uterine wall, though the clinical significance of this is unclear.

Brief, incidental exposure (such as standing with your back to a panel while treating shoulders) is not a concern. Deliberate, extended lower back treatment should be deferred until post-partum.

Pelvic Area

Direct light exposure to the pelvic region (lower abdomen, groin) should be avoided for the same precautionary reasons as abdominal exposure.

A Conservative Protocol for Pregnancy

For pregnant women who wish to continue using red light therapy for skin, facial, or upper body applications, the following protocol minimises any theoretical risk:

Acceptable Treatment Areas

Area	Trimester 1	Trimester 2	Trimester 3
Face	Acceptable	Acceptable	Acceptable
Neck	Acceptable	Acceptable	Acceptable
Hands/wrists	Acceptable	Acceptable	Acceptable
Upper back/shoulders	Acceptable	Acceptable	Acceptable
Arms	Acceptable	Acceptable	Acceptable
Feet/ankles	Acceptable	Acceptable	Acceptable
Legs (below knee)	Acceptable	Acceptable	Acceptable
Upper chest	Use caution	Use caution	Use caution
Lower back	Avoid	Avoid	Avoid
Abdomen	Avoid	Avoid	Avoid
Pelvic area	Avoid	Avoid	Avoid

Parameters

• Wavelength: 630-660nm (visible red) preferred over NIR during pregnancy, as visible red has shallower penetration depth
• Irradiance: Standard therapeutic levels (20-100 mW/cm²) on approved areas
• Session duration: Standard protocols for the treated area — no need to reduce for non-abdominal treatment
• Frequency: Standard protocols — no pregnancy-specific reduction needed for approved areas

Additional Precautions

• Avoid overheating. Extended sessions with high-power panels can raise skin temperature. During pregnancy, avoid treatment protocols that cause noticeable skin warming.
• Stay hydrated. General pregnancy advice, but worth reinforcing during any treatment that involves standing for extended periods.
• Position carefully. If using a standing panel for facial treatment, angle the panel upward so light is directed at the face/upper body only, not the abdomen.
• Skip if unwell. If experiencing pregnancy complications (preeclampsia, placental issues, pre-term labour risk), defer all elective treatments including PBM until cleared by your obstetrician.

Frequently Asked Questions

”I used red light therapy before I knew I was pregnant. Should I be worried?”

No. There is no evidence that red light therapy causes harm during early pregnancy, and the physics of light penetration make foetal exposure at meaningful irradiance levels essentially impossible. Women have been exposed to red and near-infrared light (from sunlight, indoor lighting, and various medical treatments) throughout pregnancy since the beginning of human history. A few sessions of PBM in early pregnancy is not a cause for concern.

”Can red light therapy help with pregnancy-related skin issues?”

Potentially. Conditions like pregnancy acne, melasma, and stretch marks are common. Red light therapy has evidence for skin rejuvenation and collagen synthesis (Wunsch & Matuschka, 2014), and facial treatment during pregnancy is generally considered safe. However, melasma can be worsened by heat, so low-irradiance, shorter sessions are advisable.

”What about red light therapy for post-partum recovery?”

Post-partum, the pregnancy-specific concerns no longer apply. Red light therapy for C-section scar healing, perineal recovery, skin restoration, and general well-being can follow standard adult protocols. PBM has established evidence for wound healing acceleration (Huang et al., 2009) and may support surgical scar remodelling.

”Is red light therapy safe while trying to conceive?”

The fertility evidence (discussed above) suggests that PBM may actually support conception by improving oocyte mitochondrial function. Treatment during the follicular phase and around ovulation has been used in fertility clinic settings. There are no established contraindications for PBM during the pre-conception period.

The Bottom Line

Red light therapy during pregnancy sits in a common medical grey area: no evidence of harm, but insufficient evidence to guarantee safety. The physics and biology strongly suggest that surface-level PBM treatments pose negligible risk to a developing foetus — light simply cannot reach uterine depth at meaningful irradiance levels. But “strongly suggest” is not the same as “clinically proven.”

The conservative approach is straightforward: treat above the waist (face, neck, hands, upper back, shoulders), avoid the abdomen, lower back, and pelvic area, and discuss your plans with your prenatal care provider. For non-abdominal applications, there is no physiological reason to stop red light therapy during pregnancy.

If you used red light therapy before discovering you were pregnant, there is no reason for alarm. And once you’ve delivered, standard treatment protocols apply without pregnancy-specific restrictions.

References

• Hamblin, M.R. & Demidova, T.N. (2006). Mechanisms of low level light therapy. Proceedings of SPIE, 6140, 614001.
• Henderson, T.A. & Morries, L.D. (2015). Near-infrared photonic energy penetration: can infrared phototherapy effectively reach the human brain? Neuropsychiatric Disease and Treatment, 11, 2191-2208.
• Huang, Y.Y., Chen, A.C., Carroll, J.D., et al. (2009). Biphasic dose response in low level light therapy. Dose-Response, 7(4), 358-383.
• Ohkura, T., Yamada, R., Homma, H., et al. (2012). Effect of low-level laser therapy on the reproductive system of female rats. Laser Therapy, 21(1), 23-28.
• Poormoosavi, S.M., Behmanesh, M.A., Janati, S., et al. (2017). Effect of low-level laser on folliculogenesis and ovarian tissue of the rats. Laser Therapy, 26(1), 33-40.
• Sato, T., Shimada, Y., Nagahara, N., et al. (2012). Proximal LLLT for infertility in women. Journal of Biomedical Optics, 17(2), 028002.
• Van Blerkom, J. (2011). Mitochondrial function in the human oocyte and embryo and their role in developmental competence. Mitochondrion, 11(5), 797-813.
• Wunsch, A. & Matuschka, K. (2014). A controlled trial to determine the efficacy of red and near-infrared light treatment in patient satisfaction, reduction of fine lines, wrinkles, skin roughness, and intradermal collagen density increase. Photomedicine and Laser Surgery, 32(2), 93-100.